EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Evidence-based confluence: Ayurveda, complementary medicine, and molecular oncology in cancer survivorship

Himani Sharma, Sonam Chauhan, Prachi Khandelwal, Sanjay Kumar Tiwari, Vidhi Jain, Rupesh Vishwas Gangurde, Varsharani Kadam

Ayush Journal of Integrative Oncology · 2026-01 · 3 (1) · 37-46

DOI: 10.4103/ajio.ajio_6_26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ayush Journal of Integrative Oncology, online erschienen am 16.04.2026. Verfasst von Himani Sharma und 6 weiteren Autor:innen. Die Arbeit nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer continues to be a global cause of morbidity and mortality, with a rising incidence expected to reach more than 35 million new cases annually by the year 2050. In India, the load is increasing due to late diagnosis, toxicity of treatment, and economic burden. While contemporary oncology, supported by advances in molecular oncology, has improved survival through chemotherapy, radiotherapy, and targeted/precision therapies, formidable challenges persist, including drug resistance, systemic toxicity, and compromised quality of life (QoL). Complementary and integrative medicine, especially Ayurveda, provides a biopsychosocial, patient-centric model that addresses both physical and psychosocial aspects of cancer treatment. Ayurvedic treatments such as Rasayana Chikitsa, Panchakarma, and phytotherapies (e.g., curcumin, boswellic acids, Withania somnifera , etc.) have shown immunomodulatory, anti-inflammatory, and QoL-improving effects in new clinical and observational studies. Molecular oncology gives mechanistic insights into cancer at the genomic and epigenomic levels, whereas Ayurveda offers a systems-biology approach with an emphasis on personalized, constitution-based therapy (Prakriti). Integrative research merging these paradigms has the potential to maximize therapeutic benefit, reduce treatment-related side effects, and improve survivorship. Translating molecular oncology into Ayurveda necessitates extensive randomized controlled trials, formulation standardization, strong regulatory systems, and transdisciplinary partnerships. Such evidence-based confluence can drive oncology toward a more holistic, patient-orientated paradigm, that not only cures the tumor but heals the individual.

Zitieren

APA

Sharma, H., Chauhan, S., Khandelwal, P., Tiwari, S. K., Jain, V., Gangurde, R. V., & Kadam, V. (2026). Evidence-based confluence: Ayurveda, complementary medicine, and molecular oncology in cancer survivorship. Ayush Journal of Integrative Oncology, 3(1), 37-46. https://doi.org/10.4103/ajio.ajio_6_26

Vancouver

Sharma H, Chauhan S, Khandelwal P, Tiwari SK, Jain V, Gangurde RV, et al. Evidence-based confluence: Ayurveda, complementary medicine, and molecular oncology in cancer survivorship. Ayush Journal of Integrative Oncology. 2026;3(1):37-46. doi:10.4103/ajio.ajio_6_26

BibTeX
@article{Sharma2026,
  author = {Sharma, Himani and Chauhan, Sonam and Khandelwal, Prachi and Tiwari, Sanjay Kumar and Jain, Vidhi and Gangurde, Rupesh Vishwas and Kadam, Varsharani},
  title = {Evidence-based confluence: Ayurveda, complementary medicine, and molecular oncology in cancer survivorship},
  journal = {Ayush Journal of Integrative Oncology},
  year = {2026},
  volume = {3},
  number = {1},
  pages = {37--46},
  doi = {10.4103/ajio.ajio_6_26}
}
Kostenlos starten →